Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid
Tóm tắt
This study aimed to develop breakpoints of carbapenems for intraabdominal infections, based on pharmacokinetics (PK) and pharmacodynamics (PD) at the target site. Imipenem, meropenem, and doripenem were each administered to 8–11 patients before abdominal surgery, and venous blood and peritoneal fluid samples were obtained. The drug concentrations in plasma and peritoneal fluid were determined and analyzed using population pharmacokinetic modeling. Using the pharmacokinetic model parameters, a Monte Carlo simulation was performed to estimate the probabilities of attaining the bacteriostatic and bactericidal targets (20% and 40% of the time above the minimum inhibitory concentration [MIC], respectively) in peritoneal fluid. The bacteriostatic and bactericidal breakpoints were defined as the highest MIC values at which the bacteriostatic and bactericidal probabilities in peritoneal fluid were 80% or more. The breakpoints for the minimum and maximum approved dosages of each drug were identical for imipenem, meropenem, and doripenem, and some of these values varied with dosing interval and infusion time. Site-specific PK-PD-based breakpoints are proposed here for the first time, and should help us to select appropriate carbapenem regimens for intraabdominal infections.
Tài liệu tham khảo
Arakawa S, Matsui T, Kamidono S, Kawada Y, Kumon H, Hirai K, et al. Derivation of a calculation formula for breakpoints of antimicrobial agents in urinary tract infections. J Infect Chemother 1998;4:97–106.
Arakawa S, Matsui T, Miyazaki S, Hara I, Fujisawa M, Gohji K, et al. Empiric breakpoints of antimicrobial agents in urinary tract infections. J Infect Chemother 1998;4:128–134.
Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kusano N, et al. Report of the Committee for Japanese Standards for Antimicrobial Susceptibility Testing for Bacteria: clinical breakpoints in pulmonary infections and sepsis. Jpn J Chemother 1994;42:905–914.
Saito A. Clinical breakpoints for antimicrobial agents in pulmonary infections and sepsis: report of the Committee for Japanese Standards for Antimicrobial Susceptibility Testing for Bacteria. J Infect Chemother 1995;1:83–88.
Saito A, Inamatsu T, Okada J, Oguri T, Kanno H, Kusano N, et al. Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J Infect Chemother 1999;5:223–226.
Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T. Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients. J Infect Chemother 2008;14:141–146.
Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs 2007;67:1027–1052.
Ikawa K, Morikawa N, Sakamoto K, Ikeda K, Ohge H, Takesue Y, et al. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients. Chemotherapy 2008;54:131–139.
Ikeda K, Ikawa K, Morikawa N, Miki M, Nishimura S, Kobayashi M. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:371–375.
Ikeda K, Ikawa K, Morikawa N, Kameda K, Urakawa N, Ohge H, et al. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2008;867:20–25.